TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01881282

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carraghenates Cream
Description: Carraghenates cream will be administered 3-4 gram (g) each time (one sixth of a piece) through anal canal, twice a day (once in the morning and once in the evening); for consecutive 6 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mayinglong Musk Hemorrhoid Ointment
Description: Mayinglong musk hemorrhoid ointment will be administered 2 g each time through anal canal, twice a day (once in the morning and once in the evening) for consecutive 6 days.
Study: NCT01237431

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 500ml water intake
Description: subjects have to ingest 500ml water within 5 minutes after resting 30 minutes in supine position

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 500ml water intake
Description: subjects have to ingest 500ml water within 5 minutes after resting 30 minutes in supine position
Study: NCT02530476

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor
Description: Phase I Starting Dose of Selinexor: 80 mg by mouth twice weekly for a 28 day cycle.~Phase II Starting Dose of Selinexor: Maximum tolerated dose from Phase I.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor
Description: Phase I Starting Dose of Selinexor: 80 mg by mouth twice weekly for a 28 day cycle.~Phase II Starting Dose of Selinexor: Maximum tolerated dose from Phase I.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor
Description: Phase I Starting Dose of Selinexor: 80 mg by mouth twice weekly for a 28 day cycle.~Phase II Starting Dose of Selinexor: Maximum tolerated dose from Phase I.
Study: NCT03379376

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Receive questionnaire

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Supportive Care
Description: Undergo eHealth mindful moving and breathing
Study: NCT00735761

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ME-609
Description: Dosage form: Cream Dose and regimen: 5 times daily during 5 days Route of administration: Topical application

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acyclovir in ME-609 vehicle (5% acyclovir)
Description: Dosage form: Cream Dose and regimen: 5 times daily during 5 days Route of administration: Topical application
Study: NCT02399904

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: california tri-pull taping
Description: To approximate the humeral head into the glenoid cavity participants were instructed to place their affected arm on a wooden table. Three piece of tape was used, firstly we applied cotton undercover pre tape and then we applied the rigid post tape on it. First piece (middle) of tape was applied from 1.5 inches below the deltoid tuberosity up to 2 inches above the glenoid cavity. Second piece (posterior) was applied from 1.5 inches below the deltoid tuberosity upto the 1.5 inches above the mid spine of scapula. Third piece (anterior) was applied from the 1.5 inches below the deltoid tuberosity upto the 1.5 inches above the clavicle.
Study: NCT01012349

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Association: acetylsalicylic acid (500mg), sodium bicarbonate (1625) and citric acid (965)
Description: 1 tablet in an episody of headache

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin - Bayer
Description: 1 tablet in an episody of headache (Aspirin 500mg)
Study: NCT04694183

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: 200mg, intravenous drip administration, d1, every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1
Description: Oral, d1-14, every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 130mg/m² intravenous drip administration, d1, every 3 weeks(For patients with liver and/or para-aortic lymph node metastasis).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Intraperitoneal paclitaxel 20 mg/m² and intravenous paclitaxel 50 mg/m² on days 1 and 8, every 3 weeks(For patients with peritoneal metastasis ).
Study: NCT03712839

Intervention type: OTHER
Intervention: Cognitive-functional evaluation
Description: The participants will be evaluated with a set of tools within the context of meaningful ADL.

Intervention type: OTHER
Intervention: Cognitive-functional evaluation
Description: The participants will be evaluated with a set of tools within the context of meaningful ADL.

Intervention type: OTHER
Intervention: Cognitive-functional evaluation
Description: The participants will be evaluated with a set of tools within the context of meaningful ADL.
Study: NCT00653952

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAELYX
Description: Dose of 50 mg/m2 by i.v. infusion over 1 hour every 28 days for up to 1 year

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel HCl
Description: Dose of 175 mg/m2 by i.v. infusion over 3 hours starting on Day 1 of a 21-day cy
Study: NCT04343326

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: perform corneal collagen cross linking accelerated and delivery of systemic oxygen
Description: CXL is performed using an accelerated protocol (9 mW/ CM2 for 10 minutes) in addition to the delivery of systemic oxygen with a rate of 5 liters/min through a nasal mask for 10 minutes during UV-A ablation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: perform corneal collagen cross linking accelerated and without additional oxygen therapy
Description: corneal collagen cross linking with accelerated protocol without additional oxygen therapy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: perform Conventiona corneal collagen cross linking
Description: Conventional CXL using 30 mW/CM2 UV-A ablation for 30 minutes
Study: NCT01074762

Intervention type: BEHAVIORAL
Group type: NO_INTERVENTION
Intervention: Structured personal care
Description: General practitioners (GPs) were recommended to perform regular follow up every three months and an annual screening for diabetic complications. The GP was requested to define, together with the patient, the best possible goals for blood glucose concentration, glycated haemoglobin (HbA1c), diastolic blood pressure, and lipids within three predefined categories. At each quarterly consultation, the GP was asked to compare the achievements with the goal and consider changing either goal or treatment accordingly. The doctors received annual descriptive feedback reports on individual patients. The GPs were introduced to possible solutions to therapeutic problems through clinical guidelines supported by an annual half day seminar. Patient leaflets were produced for the doctor to hand out.
Study: NCT00580216

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idrabiotaparinux sodium
Description: Pre-filled syringes containing:~* 0.5 mL for the 3.0 mg dosage;~* 0.33 mL for the 2.0 mg dosage (maintenance dosage for participants with mild renal impairment and less than 75 years old);~* 0.25 mL for the 1.5 mg dosage (maintenance dosage for participants with moderate renal impairment or age ≥75 years).~Subcutaneous injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Warfarin
Description: Capsules with 1 or 5 mg for INR-adjusted dose (INR checked at least once a month)~Oral administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo (for idrabiotaparinux)
Description: Matching pre-filled syringes containing:~* 0.5 mL for the 3.0 mg dosage;~* 0.33 mL for the 2.0 mg dosage (maintenance dosage for participants with mild renal impairment and less than 75 years old);~* 0.25 mL for the 1.5 mg dosage (maintenance dosage for participants with moderate renal impairment or age ≥75 years).~Subcutaneous injection
Study: NCT01816256

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Upper gastrointestinal endoscopy and Doppler ultrasound
Description: This is a one arm study. All patients will receive two screening tests (Doppler ultrasound, upper gastrointestinal endoscopy).
Study: NCT03099980

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: secukinumab
Description: secukinumab 300 mg (2 x 150 mg pre-filled syringe) administered at Baseline, Weeks 1, 2, 3, 4, and then Q4W for 24 weeks via subcutaneous injections
Study: NCT00580216

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (for warfarin)
Description: Warfarin matching capsules~Oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avidin
Description: Vial containing 105 mg of lyophilized powder for dilution~Intravenous infusion for 30 minutes

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo (for avidin)
Description: Vial containing 105 mg of matching lyophilized powder for dissolution~Intravenous infusion for 30 minutes
Study: NCT00912483

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: heparin sodium - Blausiegel
Description: Heparin sodium - 5.000UI/0.25mL, twice a day for 7 days and 2 hours before the surgery

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Heparin sodium - APP
Description: Heparin sodium - 5.000USP/mL, twice a day for 7 days and 2 hours before the surgery
Study: NCT03743740

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Spinal stabilization exercise
Description: The effects of spinal stabilization exercise in patients with myasthenia gravis will be investigated.There is no study in the literature that previously applied spinal stabilization exercises in patients with myasthenia gravis. The benefits of spinal stabilization exercises in other diseases are shown.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Spinal stabilization exercise
Description: The effects of spinal stabilization exercise in patients with myasthenia gravis will be investigated.There is no study in the literature that previously applied spinal stabilization exercises in patients with myasthenia gravis. The benefits of spinal stabilization exercises in other diseases are shown.
Study: NCT03110068

Intervention type: DIAGNOSTIC_TEST
Intervention: contrast-enhanced ultrasound
Description: The Aplio SSA-770A or Aplio 500 (Toshiba Medical Systems, Tokyo, Japan) equipped with a 375BT convex transducer (frequency range, 1.9 to 6.0 MHz). CHI is used with a mechanical index that ranged from 0.06 to 0.10. After activating CHI mode, a bolus injection of 2.4 ml of SonoVue (Bracco, Milan, Italy) is administered intravenously via an antecubital vein, followed immediately by a flush of 5 ml of normal saline solution. The targeted lesion should be observed continuously for 5 minutes, and the entire arterial and portal venous phases and several repetitions of the late phase are stored on the hard disk. The arterial, portal venous and late phases are defined as 0-30 s, 31-120 s and 121-360 s after the injection, respectively.

Intervention type: DIAGNOSTIC_TEST
Intervention: contrast-enhanced computed tomography
Description: The Aquilion 64-slice helical CT machine (Tokyo, Japan) is used. The imaging protocol for CT examinations is as follows: 0.5 mm × 64 mm collimation, 120 kV, 150-200 mAs for 64-slice helical CT examination. The standard triphasic scan procedure is used. An unenhanced helical sequence scan through the liver will be performed first; thereafter nonionic iodinated contrast material (Ultravist, Schering, Berlin, Germany) (1.5 mL/kg) will be administered via antecubital vein with power injection at a rate of 4 mL/s for 64-slice helical CT. The arterial phase sequence is obtained 25-32 s after contrast material administration, followed by a portal venous phase sequence 70 s after contrast agent administration.
Study: NCT02896582

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: 1000 mg D1, D8, D15 in GA-DHAP 1000 mg D-8 in GA-BEAM 1000 mg every 2 months for 3 years then every month if MRD+

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 40 mg D1 to D4 in GA-DHAP

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aracytine
Description: 2g/m² D1 \& D2 in GA-DHAP 400 mg/m² D-6 to -3 in GA-BEAM

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatinum
Description: 100 mg/m² D1 in GA-DHAP

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: 400 mg/m² D-6 to D-3 in GA-BEAM
Study: NCT01530282

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Invasive method
Description: Esophageal and gastric catheters to measure respiratory mechanics (static and dynamic)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Non invasive method
Description: Non_invasive method: airway pressure measured during a 150-200 ms at the beginning of inspiration
Study: NCT03742206

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Parasacral Transcutaneous Electrical Stimulation
Description: Electrical stimulation with surface electrodes on the sacral roots of S3 that produce inferior urinary tract neuromodulation.
Study: NCT02896582

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: 140 mg/m² D-2 in GA-BEAM

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carmustine
Description: 300 mg/m² D-7 in GA-BEAM
Study: NCT00539227

Intervention type: PROCEDURE
Intervention: NAC Sparing Mastectomy
Description: A skin-sparing mastectomy performed with preservation of the nipple-areolar complex (NAC).

Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: Questionnaires taking about 20-30 minutes to complete.
Study: NCT04276363

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Thrive Professional Learning plus ParentCorps
Description: led by the NYC Department of Education. Professional Learning sessions are tailored to the needs of pre-K teachers and leaders, and include topics aligned with the district's quality standards that support child instructional goals.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Thrive Professional Learning only
Description: Part of the Professional Learning Track system for all Pre-K for All teachers and leaders. The NYC DOE schedules Thrive Professional Learning training days for staff on non-attendance days. Teachers attend four Professional Learning days annually, and leaders attend three days annually, over a two-year period.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Inspire Professional Learning
Description: Delivered to leaders in groups of 20 - 40 three times a year over the same two-year period. Content covers best practices in Family Engagement and Social Emotional Learning and includes an experiential approach to behavior change that asks learners to take the perspective of others and consider their own beliefs and assumptions about students, families, teachers and leaders
Study: NCT04555850

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Human Thymosin β4
Description: Healthy subjects , were given a dose of rh-Tβ4 for ten consecutive days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Human Thymosin β4
Description: Healthy subjects , were given a dose of rh-Tβ4 for ten consecutive days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Human Thymosin β4
Description: Healthy subjects , were given a dose of rh-Tβ4 for ten consecutive days.

Intervention type: OTHER
Group type: OTHER
Intervention: Placebo
Description: 3 cohorts, with 6 healthy subjects , were given a dose of Placebo for ten consecutive days. Cohorts received ascending doses of either 0.5,2.0 or 5.0 ug/kg .
Study: NCT01031459

Intervention type: DRUG
Intervention: Betaseron (Interferon beta-1b, BAY86-5046)
Description: Telephone survey of all patients.
Study: NCT05896930

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meropenem 6g IV over 6 hours
Description: Meropenem 6g intravenously over 6 hours once daily on days 1-14.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ertapenem 1g IM
Description: Ertapenem 1g intramuscularly once daily on days 1-14.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meropenem 3g IV
Description: Meropenem 3g intravenously twice daily over 60 minutes on days 1-14.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ertapenem 1g IV
Description: Ertapenem 1g intravenously once daily on days 1-14.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin/CA twice daily
Description: Amoxicillin/CA 2 tablets x 1000mg/62.5mg orally 12-hourly on days 1-14.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin/CA twice daily
Description: Amoxicillin/CA 2 tablets x 1000mg/62.5mg orally 12-hourly on days 1-14.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin/CA twice daily
Description: Amoxicillin/CA 2 tablets x 1000mg/62.5mg orally 12-hourly on days 1-14.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin/CA twice daily
Description: Amoxicillin/CA 2 tablets x 1000mg/62.5mg orally 12-hourly on days 1-14.
Study: NCT04608305

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Saline Placebo (double)
Description: Two administrations of saline placebo, 28 days apart

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Saline Placebo (double)
Description: Two administrations of saline placebo, 28 days apart

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Saline Placebo (double)
Description: Two administrations of saline placebo, 28 days apart

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Saline Placebo (double)
Description: Two administrations of saline placebo, 28 days apart

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Saline Placebo (double)
Description: Two administrations of saline placebo, 28 days apart

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Saline Placebo (double)
Description: Two administrations of saline placebo, 28 days apart

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Saline Placebo (double)
Description: Two administrations of saline placebo, 28 days apart

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IIBR-100 medium-dose (prime-boost)
Description: Two administrations of IIBR-100 1\*10E6 pfu/ml, 28 days apart

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IIBR-100 medium-dose (prime-boost)
Description: Two administrations of IIBR-100 1\*10E6 pfu/ml, 28 days apart

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IIBR-100 high-dose (prime-boost)
Description: Two administrations of IIBR-100 1\*10E7 pfu/ml, 28 days apart

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IIBR-100 high-dose (prime-boost)
Description: Two administrations of IIBR-100 1\*10E7 pfu/ml, 28 days apart

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IIBR-100 top-dose (prime-boost)
Description: Two administrations of IIBR-100 1\*10E8 pfu/ml, 28 days apart

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IIBR-100 top-dose (prime-boost)
Description: Two administrations of IIBR-100 1\*10E8 pfu/ml, 28 days apart
Study: NCT03742206

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcutaneous Posterior Tibial Nerve Stimulation
Description: Electrical stimulation with surface electrodes through the activation of peripheral afferent nerves that produce inferior urinary tract neuromodulation
Study: NCT04780945

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Functional RAD51 assay
Description: ex vivo functional assay (RAD51 assay also known as Repair Capacity (RECAP) assay ) to test homologous recombination deficiencie (HRD) in viable tumor tissue
Study: NCT03128359

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate
Description: Given IV
Study: NCT05896930

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin/CA twice daily
Description: Amoxicillin/CA 2 tablets x 1000mg/62.5mg orally 12-hourly on days 1-14.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin/CA twice daily
Description: Amoxicillin/CA 2 tablets x 1000mg/62.5mg orally 12-hourly on days 1-14.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampicin 35 mg/kg
Description: Rifampicin 35 mg/kg once daily on days 1-14.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meropenem 6g IV over 60 minutes
Description: Meropenem 6g intravenously once daily over 60 minutes on days 1-14.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rifafour e-275
Description: Rifafour e-275 will be supplied as fixed dose combination tablets and administered orally once daily for 14 days as The daily dose is dependent on the participants' weight as follows: 40 - 54kg: 3 tablets; 55 - 70kg: 4 tablets; 71kg and over: 5 tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meropenem 4g IV
Description: Meropenem 4g intravenously once daily over 60 minutes on days 1-14.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin/CA once daily
Description: Amoxicillin/CA 2 tablets x 1000mg/62.5mg orally once daily on days 1-14.
Study: NCT01844739

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NVN1000 4% Gel
Description: Applied topically twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Gel
Description: Applied topically twice daily
Study: NCT04780945

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib Oral Product
Description: 300 mg bid
Study: NCT02693236

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: adenovirus-transfected autologous DC vaccine plus CIK cells
Study: NCT00554463

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: 5 mcg/kg/day IV (intravenous) days 4-13 and days 25-34 for a total of 20 doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim
Description: 6 mg via subcutaneous injection days 46 and 67

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Concurrent: 120 mg/m\^2, IV on days 1-3 and days 22-24. Adjuvant: 120 mg/m\^2, IV on days 43-45 and days 65-66.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Concurrent: 60 mg/m\^2, IV on days 1 and 22. Adjuvant: 60 mg/m\^2, IV on days 43 and 64.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: A total of 61.2 Gy in 5 weeks: Once-daily 1.8 Gy fractions for 15 fractions over 3 weeks beginning on day 1 of chemotherapy, then twice-daily 1.8 Gy fractions for 10 fractions over 2 weeks.